Cybin Inc. Management's Discussion and Analysis of Financial Condition and Operating Performance For the three and six months ended September 30, 2023 Date: November 14, 2023 CYBIN INC. Management's Discussion and Analysis This Management's Discussion and Analysis ("MD&A") has been prepared by management of Cybin Inc. ("Cybin" or the "Company") and should be read in conjunction with Cybin's interim condensed consolidated financial statements and notes for the three and six months ended September 30, 2023 (t ...

November 10, 2023 Cybin Inc. 100 King Street West, Suite 5600 Toronto, Ontario M5X 1C9 Each Unit will consist of one Common Share (as hereinafter defined) (each, a "Unit Share" and collectively, the "Unit Shares") and one Common Share purchase warrant (each, a "Warrant" and collectively, the "Warrants"). Each whole Warrant will entitle the holder thereof to purchase one additional Common Share (each, a "Warrant Share" and collectively, the "Warrant Shares"), subject to adjustment in certain circumstances, a ...

DRUG DEVELOPMENT Drug development involves long lead times, is very expensive and involves many variables of uncertainty. Anticipated timelines regarding drug development are based on reasonable assumptions informed by current knowledge and information available to the Company. Every patient treated on future studies can change those assumptions either positively (to indicate a faster timeline to new drug applications and other approvals) or negatively (to indicate a slower timeline to new drug applications ...

Cybin Inc. Management's Discussion and Analysis of Financial Condition and Operating Performance For the three months ended June 30, 2023 Date: August 11, 2023 CYBIN INC. Management's Discussion and Analysis This Management's Discussion and Analysis ("MD&A") has been prepared by management of Cybin Inc. ("Cybin" or the "Company") and should be read in conjunction with Cybin's interim condensed consolidated financial statements and notes for the three months ended June 30, 2023 (the "Interim Financial Statem ...

Cybin Inc. Management's Discussion and Analysis of Financial Condition and Operating Performance For the three and nine months ended December 31, 2022 Date: February 13, 2023 CYBIN INC. Management's Discussion and Analysis This Management's Discussion and Analysis ("MD&A") has been prepared by management of Cybin Inc. ("Cybin" or the "Company") and should be read in conjunction with Cybin's interim condensed consolidated financial statements and notes for the three and nine months ended December 31, 2022 (t ...

Cybin Inc. Management's Discussion and Analysis of Financial Condition and Operating Performance For the three and six months ended September 30, 2022 Date: November 14, 2022 CYBIN INC. Management's Discussion and Analysis This Management's Discussion and Analysis ("MD&A") has been prepared by management of Cybin Inc. ("Cybin" or the "Company") and should be read in conjunction with Cybin's interim condensed consolidated financial statements and notes for the three and six months ended September 30, 2022 (t ...

Financial Performance - For the three months ended June 30, 2022, Cybin reported a significant increase in research and development expenses, totaling CAD 2,500,000, representing a 150% increase compared to the same period last year[2]. - The total use of funds from April 1, 2022, to June 30, 2023, amounts to $57,477,000, with a significant increase in general and administrative expenses to $35,508,000[70]. - The company has negative cash flow from operating activities and may need to deploy existing working capital to fund future negative cash flows[70]. - The company expects to raise additional funds through equity securities or debt to meet its expenditure requirements[73]. - The Company has increased its estimated spending for drug development to $4,762 up to June 30, 2023, reflecting additional planned progressions[100]. Research and Development Focus - The company is focused on advancing pharmaceutical therapies for psychiatric and neurological conditions, with ongoing clinical trials aimed at confirming the safety and efficacy of its psychedelic molecules[16]. - The Company is developing a range of novel synthetic psychedelic active pharmaceutical ingredients (APIs) for major depressive disorder (MDD), alcohol use disorder (AUD), and various anxiety disorders[25]. - The Company has prioritized the Deuterated Psilocybin Analog Program over the sublingual film technology due to positive research data, merging MDD and AUD indications into a single program[39]. - The Company has transitioned its work on CYB003 into a new Deuterated Psilocybin Analog Program, targeting both Alcohol Use Disorder (AUD) and MDD indications[50]. - The Company is focused on developing psychedelic medicines and aims to grow its pipeline through internal R&D, mergers, acquisitions, and collaborative agreements[157]. Clinical Trials and Regulatory Approvals - The Company received a "may proceed letter" from the FDA for its Phase I/IIa clinical trial of CYB003, which will enroll approximately 32 participants[41]. - The Company received FDA IND clearance to commence its Phase I/IIa clinical trial evaluating CYB003 for the treatment of Major Depressive Disorder (MDD)[50]. - The anticipated timeline for the phenethylamine program to deliver a drug candidate suitable for clinical studies has been updated to Q4 2023, delayed from Q4 2022 - Q1 2023 due to research and development delays[13]. - The anticipated timeline to complete the CYB004-E Phase I DMT study is Q1 2023, with no assurance that this timeline will be met[19]. - The Company plans to file a clinical trial application in the U.S. for the Deuterated Psilocybin Analog Program after completing pre-clinical studies and CMC development[148]. Intellectual Property and Patents - The Company has one granted US patent for CYB004 and holds ten provisional patent applications, one US non-provisional patent application, and eight PCT applications[123]. - Cybin has filed patent applications for a range of novel psychedelic compounds, including 25 applications in total, with a focus on improved pharmacokinetic characteristics and safety profiles[126][128]. - The Company’s patent applications include methods for drug delivery that enhance bioavailability and optimize therapeutic outcomes[126]. Strategic Partnerships and Collaborations - The Company intends to establish strategic partnerships to advance its scientific research and intellectual property for new psychedelic compounds[25]. - The Company has established a partnership with Clinilabs to carry out the Phase I/IIa clinical trial of CYB003, the first psilocybin analog evaluated for MDD[64]. - The Company plans to collaborate with licensed third parties for clinical trials and does not handle controlled substances directly[134]. Operational Changes and Business Strategy - The company has decided to discontinue its Natures Journey business segment to prioritize research and development of psychedelic pharmaceutical products[22]. - The Company has cancelled its e-Commerce platform initiative to focus on the research and development of psychedelic molecules[55]. - The Company has decided not to progress with the Nutraceutical Products Program, focusing instead on the advancement of psychedelic molecules[85]. - The Company has established a wholly owned subsidiary in Ireland to scale up its European operations and transferred its intellectual property assets to this entity[129]. Risks and Challenges - Cybin's management anticipates continued significant losses in the future due to the speculative nature of the biotechnology industry and the early stage of product development[12]. - The company relies on third parties for clinical development activities, which introduces risks related to the success of its product candidates[12]. - Cybin's forward-looking statements are subject to various risks and uncertainties, including regulatory changes and competition from other biotechnology firms[6]. - Certain COVID-19 related risks could delay the implementation of planned objectives, potentially increasing costs for the company[74]. - The Company acknowledges that the ongoing effects of COVID-19 may impact patient recruitment for clinical trials[158].

® Cybin Announces Initiation of Kernel Flow Feasibility Study Measuring Psychedelic Effects on the Brain TORONTO, CANADA – March 31, 2022 – Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (Cybin or the Company), a biopharmaceutical company focused on progressing "Psychedelics to Therapeutics ", today announced that the first study visit has been conducted in a Cybin-sponsored feasibility study evaluating Kernel's quantitative neuroimaging technology, Flow, to measure ketamine's psychedelic effects on cerebral co ...

Cybin , Inc. (NYSE:CYBN) Q3 2022 Earnings Conference Call February 10, 2022 8:30 AM ET Company Participants Leah Gibson - VP, IR Douglas Drysdale - CEO Conference Call Participants Sumant Kulkarni - Canaccord Genuity Charles Duncan - Cantor Fitzgerald & Co. Sepehr Manochehry - Eight Capital Jason Shieh - H.C. Wainright François Brisebois - Oppenheimer Andrew Partheniou - Stifel Nicolaus Michael Okunewitch - Maxim Group Operator Good afternoon, ladies and gentlemen, and thank you for standing by. Welcome to ...

Cybin, Inc. (NYSE:CYBN) Q2 2022 Earnings Conference Call November 15, 2021 4:30 PM ET Company Participants Leah Gibson - VP of IR Doug Drysdale - CEO Aaron Bartlone - COO Mike Palfreyman - Chief R&D Officer Greg Cavers - CFO Eric So - Co-Founder, Executive Chairman and President Conference Call Participants Charles Duncan - Cantor Fitzgerald Sumant Kulkarni - Canaccord Patrick Trucchio - H.C. Wainwright Francois Brisebois - Oppenheimer Andrew Partheniou - Stifel Elemer Piros - ROTH Capital Partners Operator ...